|
Diabetes, Vol 38, Issue 9 1193-1199, Copyright © 1989 by American Diabetes Association
Hypoglycemia in IDDM
PE Cryer, C Binder, GB Bolli, AD Cherrington, EA Gale, JE Gerich and RS Sherwin
Washington University School of Medicine, St. Louis, Missouri 63110.
Hypoglycemia causes substantial morbidity and some mortality in
insulin-dependent diabetes mellitus (IDDM). It is often the limiting factor
in attempts to achieve euglycemia. The prevention or correction of
hypoglycemia normally involves both dissipation of insulin and activation
of glucose counterregulatory systems. Among the latter, glucagon plays a
primary role initially, whereas epinephrine is not critical, although it
becomes critical when glucagon is deficient. Growth hormone and cortisol
play demonstrable roles in recovery from prolonged hypoglycemia. Glucose
autoregulation may be involved in defense against severe hypoglycemia. With
respect to pathophysiology, counterregulatory systems are involved in at
least five clinical glucoregulatory syndromes. Defective glucose
counterregulation is associated with, and best attributed to, combined
deficiencies of the glucagon and epinephrine responses to plasma glucose
decrements. Almost assuredly in concert with hypoglycemia unawareness, it
results in a markedly increased frequency of severe hypoglycemia, at least
during intensive therapy of IDDM. Defined as a night to morning increase in
plasma glucose concentration, the dawn phenomenon is thought to result from
dissipation of insulin plus the effects of nocturnal growth hormone
secretion. Despite a sound rationale, the clinical relevance of the Somogyi
phenomenon has been recently questioned. The clinical impression of altered
glycemic thresholds for symptoms, i.e., patients with poorly controlled
IDDM suffer symptoms of hypoglycemia at relatively high plasma glucose
levels, whereas those with very well-controlled IDDM often tolerate
subnormal glucose levels, has received experimental support. Clearly,
hypoglycemia in IDDM is a problem that needs to be solved. Numerous issues
need to be addressed through both basic and clinical research.(ABSTRACT
TRUNCATED AT 250 WORDS)

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. Geddes, R. J. Wright, N. N. Zammitt, I. J. Deary, and B. M. Frier
An Evaluation of Methods of Assessing Impaired Awareness of Hypoglycemia in Type 1 Diabetes
Diabetes Care,
July 1, 2007;
30(7):
1868 - 1870.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Heptulla, L. M. Rodriguez, L. Bomgaars, and M. W. Haymond
The Role of Amylin and Glucagon in the Dampening of Glycemic Excursions in Children With Type 1 Diabetes
Diabetes,
April 1, 2005;
54(4):
1100 - 1107.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Whitehouse, D. F. Kruger, M. Fineman, L. Shen, J. A. Ruggles, D. G. Maggs, C. Weyer, and O. G. Kolterman
A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes
Diabetes Care,
April 1, 2002;
25(4):
724 - 730.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Allen, T. LeCaire, M. Palta, K. Daniels, M. Meredith, and D. J. D'Alessio
Risk Factors for Frequent and Severe Hypoglycemia in Type 1 Diabetes
Diabetes Care,
November 1, 2001;
24(11):
1878 - 1881.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. G. Bischof, M. Krssak, M. Krebs, E. Bernroider, H. Stingl, W. Waldhäusl, and M. Roden
Effects of Short-Term Improvement of Insulin Treatment and Glycemia on Hepatic Glycogen Metabolism in Type 1 Diabetes
Diabetes,
February 1, 2001;
50(2):
392 - 398.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M Güven, F Bayram, K Güven, and F Kelestimur
Evaluation of patients admitted with hypoglycaemia to a teaching hospital in Central Anatolia
Postgrad. Med. J.,
March 1, 2000;
76(893):
150 - 152.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. A. Testa and D. C. Simonson
Health Economic Benefits and Quality of Life During Improved Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled, Double-Blind Trial
JAMA,
November 4, 1998;
280(17):
1490 - 1496.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1989 by the American Diabetes Association.
|
|
| |
|